Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
VELCADE gets fast track status for relapsed and refractory mantle cell lymphoma
December 12th, 2004
Millennium Pharmaceuticals, Inc., (MLNM) announced that the U.S. Food and Drug Administration (FDA) has granted VELCADE fast track designation for relapsed and refractory mantle cell lymphoma, an aggressive form of non-Hodgkin lymphoma (NHL) which accounts for approximately 6% of all lymphomas. Currently, VELCADE is being evaluated as a single agent in a company-sponsored, multicenter, phase II, clinical trial for the treatment of mantle cell lymphoma in addition to multiple investigator-initiated trials. These trials are part of an ongoing research collaboration between Millennium and Johnson & Johnson Pharmaceutical Research & Development, LLC, to...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
